Additionally, this study investigates correlations between these interleukin signatures and immune cell markers such as CD8, IgKC, and CD20, as well as the immune checkpoint Programmed Cell Death Protein 1 (PD-1), to provide insights into their role in modulating the TME and influencing clinical outcomes in breast cancer. This evidence concerns the gene CD8A and breast cancer.